Health and Fitness Health and Fitness
Mon, April 23, 2012
Sun, April 22, 2012
Sat, April 21, 2012
Fri, April 20, 2012
Thu, April 19, 2012
Wed, April 18, 2012
Tue, April 17, 2012
Mon, April 16, 2012
Sun, April 15, 2012
[ Sun, Apr 15th 2012 ] - Market Wire
DaVita Announces CFO Transition
Sat, April 14, 2012
Fri, April 13, 2012
Thu, April 12, 2012
Wed, April 11, 2012
Tue, April 10, 2012
Mon, April 9, 2012
[ Mon, Apr 09th 2012 ] - Market Wire
April 11, 2012 in New York

Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference


//health-fitness.news-articles.net/content/2012/ .. -leaders-in-the-biotech-industry-conference.html
Published in Health and Fitness on Monday, April 16th 2012 at 13:46 GMT by Market Wire   Print publication without navigation


Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the... -- POINT RICHMOND, Calif., April 16, 2012 /PRNewswire/ --

Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference

[ ]

POINT RICHMOND, Calif., April 16, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: [ TSPT ]), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present at the BioCentury Future Leaders in the Biotech Industry Conference in New York on April 20, 2012 at 8:30 a.m. ET.

(Logo:  [ http://photos.prnewswire.com/prnh/20101102/SF93452LOGO ])

A live audio webcast and replay of this presentation may be accessed at [ http://www.media-server.com/m/p/dnf5o64x ] and on the Transcept Investor webpage at [ www.transcept.com ].

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit  [ www.transcept.com ].

Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Sr. Director, Corporate Communications
(510) 215-3567
[ gmann@transcept.com ]

SOURCE Transcept Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.transcept.com ]


Publication Contributing Sources